Page last updated: 2024-11-07

monobutyryl cyclic amp

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monobutyryl cyclic AMP (also known as N6-monobutyryl adenosine 3',5'-cyclic monophosphate or simply N6-Bu-cAMP) is a derivative of cyclic AMP (cAMP). It is a cell-permeable analog of cAMP. N6-Bu-cAMP has been shown to be effective in activating protein kinase A (PKA) which is a key enzyme in intracellular signaling pathways. N6-Bu-cAMP is often used in cell culture experiments as a tool to study the effects of cAMP signaling. N6-Bu-cAMP has been investigated for its potential therapeutic applications, particularly in the treatment of neurological disorders and cancer.'

monobutyryl cyclic AMP: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N(6)-butyryl-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP in which the exocyclic amino group on the purine fragment is carrying a butyryl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID115029
CHEBI ID84605
SCHEMBL ID9635980
MeSH IDM0042915

Synonyms (34)

Synonym
monobutyryl cyclic amp
n(6)-monobutyryl cyclic amp
33116-16-4
n-[9-[(4ar,6r,7r,7as)-2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]purin-6-yl]butanamide
adenosine, n-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate), sodium salt
butyramide, n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-, cyclic hydrogen phosphate, sodium salt
einecs 251-382-2
cyclic n6-monobutyryl amp, sodium salt
sodium n6-monobutyryl cyclic amp
n6-monobutyryladenosine-3',5'-cyclic monophosphoric acid
13117-60-7
n6-monobutyryl-camp
n6-monobutyryladenosine-3',5'-cyclic monophosphate
butyramide, n-(9-beta-d-ribofuranosyl-9h-purin-6-yl)-, cyclic hydrogen phosphate
n6-butyryl-3',5'-cyclic amp
cyclic n6-monobutyryladenosine-3',5'-monophosphate
n(6)-butyryl cyclic amp
n6-butyryl-camp
monobutyryl adnosine cyclic 3',5'-monophosphate
n6-butyryladenosine 3',5'-cyclic phosphate
n(6)-monobutyryl adenosine-3',5'-cyclic monophosphate
cyclic n6-monobutyryl-amp
adenosine, n-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate)
n(6)-butyryl adenosine-3',5'-cyclic monophosphate
SCHEMBL9635980
n-{9-[(4ar,6r,7r,7as)-2,7-dihydroxy-2-oxotetrahydro-2h,4h-2lambda(5)-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-9h-purin-6-yl}butanamide
n(6)-butyryl-camp
CHEBI:84605
6-mb-camp
n(6)-butanoyl-camp
n-[9-(2,7-dihydroxy-2-oxotetrahydro-2h,4h-2lambda~5~-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl)-9h-purin-6-yl]butanimidic acid
DTXSID60927103
Q27157909
n-(9-((4ar,6r,7r,7as)-2,7-dihydroxy-2-oxidotetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl)-9h-purin-6-yl)butyramide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In vitro, the antagonist had no detectable agonist activity in the concentration used, had no effect on the maximal LH release which can be induced by LRH and shifted the dose-response line of LRH to the right, without changing its slope."( Effect of pretreatment of long-term ovariectomized rats with an LRH antagonist on LH release in vitro by LRH, elevated K+ or N6-monobutyryl adenosine 3',5'-monophosphate (mbcAMP) plus theophylline.
van Dieten, JA; van Rees, GP, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
protein kinase agonistAn agonist that selectively binds to and activates a protein kinase receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
3',5'-cyclic purine nucleotide
adenyl ribonucleotideA purine riboncleotide where adenine is the purine.
butanamidesA fatty amide derived based on a butanamide skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (64.15)18.7374
1990's14 (26.42)18.2507
2000's3 (5.66)29.6817
2010's2 (3.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.10 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]